Danish pharmaceutical giant Novo Nordisk has announced a plan to invest $4.1 billion (€3.8 billion) to expand its US manufacturing capacity. The new plant will be a second fill and finishing facility for high-in-demand weight loss drugs like Wegovy and Ozempic in Clayton, North Carolina. Novo Nordisk’s decision to invest in the US comes as part of its broader strategy to enhance its global manufacturing network. The medical firm states that: “Marking one of the largest manufacturing investments in Novo Nordisk’s history, the expansion will add 1.4 million square feet of production space for as…